Fresenius Kabi has sold its German subsidiary CFL GmbH to NewCo Pharma GmbH, a compounding company founded by pharmacist Michael Schill. Both companies specialize in IV oncology drug compounding.

Fresenius Kabi will remain active in compounding. In Germany, the focus will be on parenteral nutrition products.

In 2014, CFL had sales of EUR 77 million ($88 million). Financial terms of the transaction were not disclosed. ,/p>

Source: Fresenius Kabi